Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6Colorectal Neoplasms 5Neoplasms 4Stomach Neoplasms 3Malnutrition 3Lung Neoplasms 3Diarrhea 3Uterine Cervical Neoplasms 2Mucositis 2Inflammation 2Enteritis 2Chalazion 2Carcinoma, Hepatocellular 2Thyroid Neoplasms 1Squamous Intraepithelial Lesions 1Smoldering Multiple Myeloma 1Radiation Injuries 1Psychological Well-Being 1Psoriasis Vulgaris 1Polycystic Ovary Syndrome 1Periampullary Carcinoma Nos 1Pelvic Neoplasms 1Pelvic Inflammatory Disease 1Papillomavirus Infections 1Ovarian Neoplasms 1Neoplasms, Second Primary 1Muscle Invasive Bladder Cancer (MIBC) 1Multiple Myeloma 1Motor Activity 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

toripalimab 2zanidatamab 1tislelizumab 1disitamab vedotin 1Probiotics 1Gemcitabine 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle Invasive Bladder Cancer (MIBC) × Probiotics × Clear all
NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
146 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡